[1] 王倩,侯大为.口腔鳞状细胞癌发病及转移机制研究进展[J].口腔医学研究,2018,34(11):1164-1167. [2] Allemani C,Matsuda T,Di CV,et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J]. Lancet,2018,391(10125):1023-1075. [3] Shahruzaman SH,Fakurazi S,Maniam S. Targeting energy metabolism to eliminate cancer cells [J]. Cancer Manag Res,2018,10:2325-2335. [4] Diaz-Ruiz R,Rigoulet M,Devin A. The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression [J]. Biochim Biophys Acta,2011,1807(6):568-576. [5] Alayev A,Berger SM,Holz MK. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation [J]. Ann N Y Acad Sci,2015,1348(1):116-123. [6] Jiang S,Zou Z,Nie P,et al. Synergistic effects between mTOR complex 1/2 and glycolysis inhibitors in non-small-cell lung carcinoma cells [J]. PLoS One,2015,10 (7):e0132880. [7] Yu L,Chen X,Sun X,et al. The glycolytic switch in tumors: how many players are involved [J]. J Cancer,2017,8(17):3430-3440. [8] Abd El-Hafez YG,Moustafa HM,Khalil HF,et al. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma [J]. Oral Oncol,2013,49(3):261-268. [9] Dong G,Mao Q,Xia W,et al. PKM2 and cancer: The function of PKM2 beyond glycolysis [J]. Oncol Lett,2016,11(3):1980-1986. [10] He XY,Yin YR,Shi SS,et al. The mTOR pathway regulates PKM2 to affect glycolysis in esophageal squamous cell carcinoma [J]. Technol Cancer Res Treat,2018,17:1-10. [11] Cheng KY,Hao M. Mammalian target of rapamycin (mTOR) regulates transforming growth factor-β1 (TGF-β1)-induced epithelial-mesenchymal transition via decreased pyruvate kinase M2 (PKM2) expression in cervical cancer cells [J]. Med Sci Moni,2017,23:2017-2028. |